Short communicationIfosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcoma
References (15)
- et al.
Cytokine induction by 41.8 °C whole body hyperthermia
Cancer Lett
(1995) - et al.
A new technological approach to radiant heat whole body hyperthermia
Cancer Lett
(1994) - et al.
Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum (II) cytotoxicity on humanderived breast carcinoma and sarcoma xenografts in nude mice
J Cancer Res Clin Oncol
(1992) - et al.
Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide
Cancer Res
(1993) - et al.
Thermal enhancement of tetraplatin and carboplatin in human leukemia cells in vitro
Int J Hyperhermia
(1990) - et al.
Whole body hyperthermia and carboplatin: cytotoxicity for murine leukemia and normal marrow
Br J Cancer
(1991) - et al.
Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats
Cancer Res
(1991)
There are more references available in the full text version of this article.
Cited by (61)
An insight into the agents used for immunomodulation and their mechanism of action
2023, How Synthetic Drugs Work: Insights into Molecular Pharmacology of Classic and New PharmaceuticalsEnhancing autophagy in Alzheimer's disease through drug repositioning
2022, Pharmacology and TherapeuticsWhole-body hyperthermia in combination with systemic therapy in advanced solid malignancies
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :The remaining 14 studies combined WBH with systemic therapy in patients with a specific malignancy (phase II). For ovarian cancer (n = 3 (Atmaca et al., 2009; Douwes et al., 2004; Westermann et al., 2001)), colorectal cancer (n = 2 (Hegewisch-Becker et al., 2002; Hildebrandt et al., 2004)), lung cancer (n = 2 (Engelhardt et al., 1982; Neumann et al., 1982)) and sarcoma (n = 3 (Bull et al., 1992; Westermann et al., 2003; Wiedemann et al., 1996)) more than one trial has been performed. Single studies are available for cervical cancer (Richel et al., 2004), pancreatic cancer (Bakshandeh-Bath et al., 2009), melanoma (Engelhardt et al., 1990) and pleural mesothelioma (Bakhshandeh et al., 2003) (Table 2).
Systematic review about complementary medical hyperthermia in oncology
2022, Clinical and Experimental Medicine
Copyright © 1996 Published by Elsevier Ltd.